Anti-Human TGF-β Recombinant Antibody (Fresolimumab) (CAT#: TAB-140)

Figure 1 Mean serum concentrations of fresolimumab over time are presented by dose.

Mean serum fresolimumab concentration over time.

Trachtman, H., Fervenza, F. C., Gipson, D. S., Heering, P., Jayne, D. R., Peters, H.,... & Heaton, J. P. (2011). A phase 1, single-dose study of fresolimumab, an anti-TGF-β antibody, in treatment-resistant primary focal segmental glomerulosclerosis. Kidney international, 79(11), 1236-1243.

Figure 2 Study design and pharmacokinetics of fresolimumab in two dosing groups.

(A) Trial protocol for each group shows dosing levels and frequency and timing of skin biopsies. Red arrows indicate skin biopsies. (B) Fresolimumab levels measured in sera at 3, 7, 11, 17, and 24 weeks in group 1, which received 2 doses of 1 mg/kg at weeks 0 and 4 (blue diamonds), and group 2, which received a single dose of 5 mg/kg fresolimumab at week 0 (red squares). Error bars indicate SD.

Rice, L. M., Padilla, C. M., McLaughlin, S. R., Mathes, A., Ziemek, J., Goummih, S.,... & Spiera, R. F. (2015). Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients. The Journal of clinical investigation, 125(7), 2795-2807.

Figure 3 Small-animal PET with 89Zr-fresolimumab showed tumor uptake in both CHO-Cl2 and CHO-Cl11S (A and C, respectively; arrow indicates tumor).

Tumor uptake and organ distribution of 89Zr-fresolimumab and control 111In-IgG as quantified ex vivo (B and D, respectively).

Munnink, T. H. O., Arjaans, M. E., Timmer-Bosscha, H., Schröder, C. P., Hesselink, J. W., Vedelaar, S. R.,... & de Vries, E. G. (2011). PET with the 89Zr-labeled transforming growth factor-β antibody fresolimumab in tumor models. Journal of Nuclear Medicine, 52(12), 2001-2008.